Foxglove has been given a critical trial by physicians for 158 years, yet a definite solution has not been found for two questions concerning its use. When should the drug be started, and how long continued in patients with heart disease who have regular rhythm? Even British cardiologists, long skeptical of its use except in auricular fibrillation, now grant that it seems occasionally to benefit congestive failure in such cases. But Lewis,1 in his recent book on heart disease, deprecates giving digitalis in heart cases "merely because they are heart cases." He states that there is no evidence that digitalis, in doses up to 1.3 cc. of the tincture daily, affects the progress of congestive failure, with regular rhythm, at any stage in the course of the disease. This opinion, from one who has had notable success in elucidating clinical problems by experimental methods, is based wholly on his
THE CONTINUED USE OF DIGITALIS IN PATIENTS WITH REGULAR RHYTHM. JAMA. 1933;100(22):1770–1771. doi:10.1001/jama.1933.02740220036012
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: